SEC Form 4 · accession 0001213900-26-077636
REGENTIS BIOMATERIALS LTD. · RGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pini Ben-Elazar
Director
Period of report
Jul 9, 2026
Accepted (ET)
Jul 13, 2026 · 5:07 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001912966
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2,F5 | $2.16 | Jul 9, 2026 | A | 24,826 | A | Sep 4, 2026 | Jun 4, 2036 | Ordinary Shares | 24,826 | 24,826 | D |
| Employee Stock Option (Right to Buy)F3,F4,F5 | $0.003 | Jul 9, 2026 | A | 8,313 | A | Feb 23, 2026 | Feb 23, 2036 | Ordinary Shares | 8,313 | 8,313 | D |
Explanation of responses
- F1This option grant was approved by the Board of Directors of the Issuer on June 4, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
- F2This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on September 4, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or June 4, 2029.
- F3This option grant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026.
- F4This option grant is fully vested as of this date.
- F5To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.